Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results Meeting Abstract


Authors: Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; Modi, S.; Seidman, A.; Drullinsky, P.; Partridge, A.; Schapira, L.; Wulf, G.; Gilewski, T.; Atieh, D.; Mayer, E.; Isakoff, S.; Sugarman, S.; Fornier, M.; Traina, T.; Bromberg, J.; Currie, V.; Robson, M.; Burstein, H.; Overmoyer, B.; Ryan, P.; Kuter, I.; Younger, J.; Schumer, S.; Tung, N.; Zarwan, C.; Schnipper, L.; Chen, C.; Winer, E.; Norton, L.; Hudis, C.
Abstract Title: Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
Meeting Title: 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Journal Title: Cancer Research
Volume: 69
Issue: 2 Suppl.
Meeting Dates: 2008 Dec 10-14
Meeting Location: San Antonio, TX
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2009-01-01
Start Page: 189S
Language: English
ACCESSION: ISI:000262583200396
PROVIDER: wos
DOI: 10.1158/0008-5472.SABCS-2108
Notes: --- - Meeting Abstract: 2108 - Suppl. S - "Source: Wos"
Altmetric Score